CTOs on the Move

Nuvation Bio

www.nuvationbio.com

 
Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio`s proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world`s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
David Hanley
 Chief Technical Operations Officer Profile

Funding

Nuvation Bio raised $500M on 10/21/2020

Similar Companies

DYNAMIS THERAPEUTICS

DYNAMIS THERAPEUTICS is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthnet Solutions

Healthnet Solutions is a Bloomfield Hills, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Q-Chuck Technologies

Q-Chuck Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Curve Biosciences

Curve Biosciences (“Curve”), a company bringing precision to chronic disease care, creates products targeting biological changes in tissues that result in the development and progression of chronic diseases. Curve`s Chronic Disease Tissue Atlas (CDTA) uniquely allows the company to discover these precise changes with data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on first commercializing its best-in-class blood tests for the $30 billion market of chronic liver diseases while using CDTA to find biomarkers and targets for other conditions.

Antios Therapeutics

Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its lead oral drug candidate for a potentially curative treatment of HBV infections.